ReviewAnnals of nuclear medicine2026
Clinical applications and future directions of Iodine-131-Metaiodobenzylguanidine therapy in neuroblastoma: from salvage treatment to frontline integration.
Review in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond radiotheranostics: how imaging modality defines theranostics.European radiology experimental · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma is the most common extracranial solid tumor in children and often requires complex, multimodal treatment. A major advancement in its treatment has been the development of metaiodobenzylguanidine (MIBG), a norepinephrine analog, for diagnostic imaging and targeted radiotherapy. This review provides a comprehensive overview of the clinical applications and recent advancements of 131I-MIBG in neuroblastoma treatment. The agent has exhibited substantial efficacy in newly diagnosed and relapsed or refractory disease, through strategies such as monotherapy, tandem dosing, and high-dose administration with stem cell transplantation support. Combination regimens incorporating radiosensitizers, chemotherapeutic agents, and novel targeted approaches-including histone deacetylase inhibitors and immunotherapy-have further broadened its therapeutic scope. Challenges remain, including nonavid tumors, radiation-related risks, and logistical constraints. However, with the recent regulatory approval of 131I-MIBG for neuroblastoma treatment in Japan, its role is expected to expand, paving the way for improved outcomes and more personalized, targeted approaches in pediatric oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.